Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST: Bevacizumab for Radionecrosis
NCT02490878Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2016
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bevacizumab in radionecrosis (RN), sponsored by Cancer and Leukemia Group B. Started Apr 2016; status: terminated.
02
Drugs
bevacizumab
03
Conditions
radionecrosis (RN)
Beyond the preview
Go deeper on NCT02490878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490878.